Alto Neuroscience (ANRO) stock

Psychiatry medicines , market cap $921M

Psychiatry medicines

Market cap $921M

$22.19

-1.81%

After-hours $22.19 0.00%

As of 5:14 PM ET after-hours, delayed 15+ min · Live for Pro members

Quality Score

-6

Poor

In its industry

#86of 92

Pharma

Checks firing

1of 14

Trending up

From 52-week high

-40.8%

Below the 200-day

ANRO's Quality Score rose 1 point on Mon, Nov 2, to -6.

Follow ANRO's trial news. Pro members can get an alert when Alto Neuroscience files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ANRO files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEarly 2027“…Alto remains on track to initiate its Phase 3 trial of ALTO-207 as adjunctive treatment in TRD by early 2027…”Trial start · SEC filing · Aug 12

Why is ANRO up?

Up 58% in a year while the S&P 500 rose 12%.

Its filed figures weakened while the shares beat the market.

No filing or news in our sources explains it.

Sources: Price history, Oct 30, 2026; Quarterly reports, Jun 30, 2026

The other side, how the business stands, the timeline, and its peers, for Pro members.

Key facts on ANRO

Key facts on ANRO
Holding it back	58.1% more shares than a year ago
Latest filing	10-Q, Aug 12 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind ANRO's -6, free with an account →4 more reasons behind ANRO's -6, for Pro members.

ANRO catalysts

Coming up

After its last 4 reports it closed +4.6% on average, higher 3 of 4 times.

5 more coming up and 2 past catalysts since 2026, with sizes and sources, for Pro members.Get in free →

What's next for ANRO, and how long its cash lasts

Next step the company has named

Early 2027“…TRD trial) : Alto remains on track to initiate its Phase 3 trial of ALTO-207 as adjunctive treatment in TRD by early 2027, following alignment with the FDA on the planned trial…”Trial start · SEC filing · Aug 12

What it means: when a trial begins, or reaches the stage the company named.

Lead program: ALTO-207 · Treatment-resistant Depression (TRD) · Phase 2
Its trial: ALTO-207 in Adults With Treatment-resistant DepressionPhase 2 · Recruiting · 178 people · main data estimated Nov 2027 · NCT07553637

3 more trials, 1 with data due this year, 4 more milestones and 30 filings, for Pro members.

Cash runway

The company says its cash lasts through 2030 (8-K, Aug 12).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Feb 3, 2025)
At-the-market share sales program (S-3, filed Feb 3, 2025)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

CFO Nicholas Conrad Smith sold 134,886 shares on Sep 30.

From Form 4: open-market buys and sales only.

Get an alert when Amit Etkin buys or sells

For Pro members: every trade, and Amit Etkin’s 12 filings and quotes.

Get an alert when ANRO files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why ANRO scores -6

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

-6 is below -5, off the left end of the scale.

+1Chart checks 1 of 14 firing right now, one point each
−2Dilution 58.1% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.

Long-term trend subtracts
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
Insider trades subtracts

No effect today: Run-up, Size, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on ANRO and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 5:14 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when ANRO's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ANRO and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

ANRO has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ANRO, and all 14 on every stock.Get in free →

ANRO RSI today: 37.9, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1437.9
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 9 sessions ago.
50-day average$28.03
The price is 20.8% below it.
200-day average$24.28
The price is 8.6% below it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Sep 11, 2025.
ADX 1426.6
25 or more, with +DI below -DI.
Support$21.45
Swing low from Oct 23, 3.3% below the price.
Resistance$23.87
Swing high from Apr 1, 7.6% above the price.
52-week high$37.48
From Aug 25, 68.9% above the price.
52-week low$10.20
From Nov 4, 2025, 54.0% below the price.
Chart patternWedge
Lines over the Sep 2 and Oct 21 highs and under the Aug 3 and Oct 23 lows.
Bollinger Bands (20, 2)Inside
The bands run from $21.28 to $24.69.
Volume0.8x
Against its 20-day average, for the time of day.

The deep dive on ANRO

What it does and how it makes money2 findingsA net loss of $84.2M over the four quarters to Jun 30, 2026, with no sales on file.Income statements to Jun 30, 2026, filed Aug 12, 2026
Where it stands3 findingsFor Pro members3 findings on where ANRO stands: its cash, debt, and share count, for Pro members
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades ANRO, for Pro members

7 more findings on ANRO, each with its source, for Pro membersGet in free →

How ANRO ranks in Pharma

ANRO is #86 of 92 by Quality Score.

How ANRO ranks in Pharma
1	ABBVAbbVie	6/14	21
2	LLYEli Lilly	6/14	20
3	GMABGenmab	5/14	18
	ALMSAlumis		Open for its score
	ANNXAnnexon		Open for its score
	APMDApnimed		Open for its score
	ARDXArdelyx		Open for its score
86	ANROAlto Neuroscience	1/14	-6

When does ANRO report earnings, and what happens after?

Expected to report Wed Nov 11, after the close (in 9 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ANRO reported on Aug 12, 2026

The quarter

The figures are not read from the release yet.

The filing on EDGAR

Where the sales came from

ANRO's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“Alto expects to initiate this trial in the second half of 2027 pending alignment with the FDA.”

From its results filing (SEC filing · Aug 12)

The numbers

Market value: $921M; today
Free cash flow: -$68.8M; last 12 months

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ANRO: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

+9.1%-7.2%+10.7%

Mar 16May 13Aug 12

Reported	When	Gap	Reaction	5 sessions
Aug 12, 2026After close	After close	+2.8%	+10.7%	+19.6%
May 13, 2026Before open	Before open	-2.9%	-7.2%	-17.0%
Mar 16, 2026Before open	Before open	+1.2%	+9.1%	-3.5%

ANRO closed higher after 3 of its last 4 reports.

All 4 reports, and ANRO's Quality Score going into each

Everyone reporting earnings next week

ANRO share count over time

Shares: 58.1% more than a year ago (to Jun 30).

Shares of ANRO outstanding, as filed
Shares outstanding	As of
39.2M	Aug 7, 2026
35.1M	May 8, 2026
31.9M	Mar 9, 2026
31.1M	Nov 7, 2025

Offerings, shelves, and splits of ANRO, from its filings
From its filings	Filed
Priced a sale of shares	Jul 14, 2026
Registered shares for a later sale (S-3)	Apr 10, 2026
Registered shares for a later sale (S-3)	Nov 28, 2025
Registered shares for a later sale (S-3)	Feb 3, 2025

2 more offerings on file, for Pro members.

Insiders trading ANRO

ANRO insider trades

One insider sold $3.6M across 3 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellNicholas Conrad Smith$2.9MPresident and CFOat $26.58 on Sep 29, filed Oct 1

SellNicholas Conrad SmithPresident and CFO$2.9Mat $26.58 on Sep 29, filed Oct 1

All 3 insider filings on ANRO from the last six months, for Pro members.Get in free →

All ANRO insider trades

ANRO's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Amit EtkinPresident and CEO
Nicholas Conrad SmithPresident and CFO · 3 trades

See insider trades by person

Which ETFs hold ANRO?

In ETFs: ANRO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Alto Neuroscience

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

68 employeesMountain View, CAaltoneuroscience.com

ANRO's score card

Alto Neuroscience (ANRO): Quality Score -6, Poor, #86 of 92 in Pharma, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn ANRO's score around: 8 things
6 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 1Nicholas Conrad Smith sold ANRO$2.9M at $26.58, filed Oct 1

Alerts are optional.

See ANRO's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: ANRO's Quality Score is -6 (Poor), #86 of 92 in Pharma. Insiders sold $3.6M in the last 6 months (Form 4).

Is ANRO a good stock to buy? What its Quality Score says

ANRO scores -6 today, which Breakaway calls Poor. It is #86 of 92 in Pharma by Quality Score, with 1 of 14 chart checks firing. Up 58% in a year while the S&P 500 rose 12%. Shares: 58.1% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ANRO's Quality Score?

ANRO scores -6 today, which Breakaway calls Poor (below zero). That is #86 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ANRO's -6.

Are insiders buying ANRO?

One insider sold $3.6M across 3 filings in the last 6 months. No open-⁠market buys on record. The newest is Nicholas Conrad Smith, President and CFO, who sold $2.9M on Sep 29. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.